Merck Hints at New Cancer Drug Trial
Merck briefly shared details about a new cancer treatment trial, then quickly removed the information.
Merck, a major drug company, might test a new cancer drug combination. The company briefly released details about a trial on a government website. Then, it removed the information.
The trial would test two drugs together. One drug is a PD-1xVEGF bispecific antibody. The other is a TROP2 ADC. These drugs fight cancer in different ways. Combining them could make the treatment stronger.
Merck has kept its plans secret for almost two years. The brief post gave the first real clues about its next steps. This suggests Merck is getting ready to test this new drug combination in people.
Developing new cancer treatments matters for many patients. This new trial could lead to better ways to fight serious diseases. Investors and patients will watch for official news from Merck.
Source: FierceBiotech
More from Biotech
